肝细胞癌筛查:从当前标准诊疗到未来方向
本文为叙述性综述,面向诊断与介入放射科,总结肝细胞癌筛查指南及其近期演变。当前推荐对高危人群采用超声联合或不联合甲胎蛋白筛查;超声对肥胖或代谢功能障碍相关脂肪性肝病(MASLD)患者效能较低。对比增强超声与简化MRI方案等新影像方法可能提高检出,风险分层及新方法验证有望推动指南调整。
要点
- 高危人群推荐超声联合或不联合甲胎蛋白筛查。
- 超声对肥胖及MASLD患者早期病灶检出效能较低。
- 对比增强超声与简化MRI方案可能提高检出。
核心结论
- 当前高危人群筛查以超声联合或不联合甲胎蛋白为标准;对比增强超声和简化MRI方案等新影像方法可能改善检出,风险分层与新方法验证可能推动筛查指南调整。
研究设计与样本
- 叙述性综述,以诊断与介入放射学为视角,总结肝细胞癌筛查指南及其近期演变,并highlight新兴影像方法作为未来潜在筛查工具。
诊断标准与关键数值
- 推荐对高危人群采用超声联合或不联合甲胎蛋白进行筛查。
- 非肝硬化MASLD及慢性丙型肝炎患者也可发生肝细胞癌,但发生率不足以按当前标准支持筛查。
局限性
- 超声不能捕获所有早期病灶,且在肥胖或MASLD等特定人群中效能较低。
- 非肝硬化MASLD和慢性丙型肝炎患者发生肝细胞癌率不足以按当前标准支持筛查。
- 风险分层及新影像方法需经临床试验评估与验证,才可能推动筛查指南调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Hepatocellular carcinoma (HCC) represents a significant portion of global cancer incidence and mortality. Screening with ultrasound with or without alpha-fetoprotein is recommended for those at high-risk. Although screening can lead to earlier treatment and better outcomes, existing screening paradigms have several flaws. Ultrasound does not capture all early lesions and has lower efficacy in specific populations such as patients with obesity or those with metabolic dysfunction-associated steatotic liver disease (MASLD). Additionally, individuals with noncirrhotic MASLD and chronic hepatitis C also develop HCC, although not at high enough rates to justify screening based on current standards. These individuals, however, represent a substantial proportion of new HCC cases given rising MASLD rates and the endemic nature of hepatitis C in certain regions. Risk-stratifying these populations may reveal subsets that are higher risk and warrant screening. Several imaging advances, including contrast-enhanced ultrasound and abbreviated MRI protocols, may improve detection compared with the current approach. Evaluation of risk stratification and validation of these new imaging methods via clinical trials would likely lead to adjusting screening guidelines. This narrative review provides a diagnostic and interventional radiology-focused summary of the HCC screening guidelines and their recent evolution and highlights emerging imaging methods as potential screening tools of the future.
引用
- Mohnasky M, Gad S, Moon A, et al. Hepatocellular Carcinoma Screening: From Current Standard of Care to Future Directions. J Am Coll Radiol. 2025. PMID: 40044304. doi:10.1016/j.jacr.2024.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。